SOD1-G128R_K7-4L-f, SOD1-G128R
ICGi022-A-1
General
Cell Line |
|
| hPSCreg name | ICGi022-A-1 |
| Cite as: | ICGi022-A-1 (RRID:CVCL_D0VR) |
| Alternative name(s) |
SOD1-G128R_K7-4L-f, SOD1-G128R
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
WAe009-A-1P (IsoHD-30Q-NGN2) WAe009-A-1Q (IsoHD-65Q-NGN2) GIBHi002-A-1 (C5-PARK2-KO) WAe009-A-1R (IsoHD-81Q-NGN2) STBCi026-A-1 (SFC840-03-03 LRRK2-/-D10) STBCi026-A-2 (SFC840-03-03 LRRK2-/-C11) STBCi026-A-3 (SFC840-03-03 LRRK2 WT/R1441C H3) SIGi001-A-13 (iPSC0028 – MonoAllelic MAPT_Ex10+16T/Clone 1D01-11) BIONi037-A-2 (BIONi037-A ApoE2/2 #M10-7) BIONi037-A-3 (BIONi037-A ApoE3/4 #P10-22) BIONi037-A-4 (BIONi037-A ApoE4/4 #I10-53) BIONi037-A-1 (16423 ApoE KO) |
| Last update | 24th June 2022 |
| User feedback | |
Provider |
|
| Generator | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
External Databases |
|
| BioSamples | SAMEA9333558 |
| Cellosaurus | CVCL_D0VR |
| Wikidata | Q123032655 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
The donor is not affected.
Synonyms
|
| Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Exome sequencing
https://www.ncbi.nlm.nih.gov/sra/?term=SRR11413027 No disease associated mutation found |
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMN14446266 |
Ethics
Also have a look at the ethics information for the parental line
ICGi022-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | IDT crRNA and tracrRNA were used for CRISPR/Cas9 gene editing |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
ICGi022-A.
|
|
| Passage number reprogrammed | 1 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | ESC-like morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | |||||||||||||||
| Feeder cells |
Mouse embryonic fibroblasts Cellfinder Ont Id: http://www.ebi.ac.uk/efo/EFO_0004040 |
|||||||||||||||
| Passage method |
Enzymatically
TrypLE
|
|||||||||||||||
| O2 Concentration | 20 % | |||||||||||||||
| CO2 Concentration | 5 % | |||||||||||||||
| Medium |
Other medium:
Base medium: Knock-out DMEM
Main protein source: Knock-out serum replacement Serum concentration: 15 % Supplements
|
|||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
|||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
|||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| SOX2 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| TRA 1-60 |
Yes |
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Morphology pictures
Method documentation
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
Synonyms
Genetic modifications
SOD1 (target)Isogenic modification
21q22.11
NC_000021.9:c382G>C
NP_000445.1:pGly128Arg
Heterozygous
This mutation has been linked to ALS only once (PMID: 20192886) and has been described as highly severe with rapid progression, pain syndrome, and predominant lower motor neuron implication.
It has been predicted bioinformatically that this substitution induces changes in the structure of the electrostatic loop, which binds copper ions essential for both stability and enzymatic activity of SOD1 protein
Mutated
G128R allele seq.png
Part of the SOD1 gene sequence of one of the alleles. Single nucleotide substitution, which leads to the amino acid substitution is present |
| Genetic modifications not related to a disease |
SOD1 (target)Isogenic modification
21q22.11
NC_000021.9:c385_386delinsTG
NP_000445.1:pLys129Ter
Heterozygous
The substitution of the two amino acids in the SOD1 gene was introduced as a result of CRISPR/Cas9-induced break repair. This substitution leads to the termination codon formation and, supposedly, translation of the truncated variant of SOD1 polypeptide.
Mutated
K129Ter allele seq.png
Part of the SOD1 gene sequence of one of the alleles. Two nucleotide substitution, which leads to the termination codon formation is present |
Login to share your feedback, experiences or results with the research community.